Altimmune (ALT) Share-based Compensation (2010 - 2026)
Altimmune (ALT) posted quarterly Share-based Compensation of $20.6 million for Q1 2026, up 413.08% year-over-year from $4.0 million in Q1 2025, and up 316.92% quarter-over-quarter from $4.9 million in Q4 2025.
Altimmune (ALT) Share-based Compensation (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Share-based Compensation for 17 consecutive years, with $20.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 413.08% year-over-year to $20.6 million; the TTM figure through Mar 2026 stood at $20.6 million (up 80.61% YoY), while the FY2025 annual figure was $19.7 million, up 12.57% from the prior year.
- Share-based Compensation climbed to $20.6 million in Q1 2026 per ALT's latest filing, from $4.9 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $20.6 million in Q1 2026 and bottomed at $2000.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $5.2 million across 5 years, with a median of $3.1 million in 2024.
- Annual changes were most pronounced in 2024 — Share-based Compensation tumbled 99.98% — and 2025, when it soared 246950.0%.
- Altimmune's Share-based Compensation stood at $1.9 million in 2022, then jumped by 435.84% to $10.1 million in 2023, then sank by 99.98% to $2000.0 in 2024, then jumped by 246950.0% to $4.9 million in 2025, then soared by 316.92% to $20.6 million in 2026.
- Business Quant data shows ALT's Share-based Compensation at $20.6 million in Q1 2026, $4.9 million in Q4 2025, and $20.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.79 Mn |
| Jun 30, 2026 | 2.79 Mn |
| Mar 31, 2026 | 20.60 Mn |
| Mar 31, 2026 | 20.60 Mn |
| Dec 31, 2025 | 4.94 Mn |
| Dec 31, 2025 | 4.94 Mn |
| Sep 30, 2025 | 20.20 Mn |
| Sep 30, 2025 | 20.20 Mn |
| Jun 30, 2025 | 3.57 Mn |
| Jun 30, 2025 | 3.57 Mn |
| Mar 31, 2025 | 4.02 Mn |
| Mar 31, 2025 | 4.02 Mn |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 3.08 Mn |
| Sep 30, 2024 | 3.08 Mn |
| Jun 30, 2024 | 4.31 Mn |
| Jun 30, 2024 | 4.31 Mn |
| Mar 31, 2024 | 3.65 Mn |
| Mar 31, 2024 | 3.65 Mn |